ArticleCardiovascular intervention and therapeutics2026
One-year outcomes of the RESILIA balloon-expandable transcatheter valve: survival, hemodynamics, and hypoattenuated leaflet thickening.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk Stratification in Cardiovascular Medicine for Prognostic Assessment and Therapeutic Decision-Making: From Atrial Fibrillation to the Broader Disease Spectrum.Journal of arrhythmia · 2026Review
- A looming wave of bioprosthetic transcatheter valve failure?-rethinking lifetime management and reintervention in aortic stenosis.Journal of visualized surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Performance evaluation of the latest fifth-generation SAPIEN 3 Ultra RESILIA (S3UR) valve in patients who underwent transcatheter aortic valve replacement (TAVR) is limited. The aim of this study was to compare the 1-year clinical outcomes, including valve performance, in patients undergoing TAVR with the S3UR compared to the SAPIEN 3 or SAPIEN 3 Ultra (S3/S3U). Patients with severe native aortic stenosis who underwent TAVR with either the S3UR or the S3/S3U valve were matched using propensity scores. Predictors of 1-year outcomes were identified. A subgroup analysis of patients who underwent post-TAVR CT was conducted. Among 4,908 patients, 312 matched pairs were assessed. At 1-year, compared to the S3/S3U group, the S3UR group exhibited lower all-cause mortality (HR: 0.42; 95% CI: 0.18-0.96; p = 0.041). The S3UR group demonstrated superior hemodynamic performance, including lower transvalvular gradients, larger effective orifice areas, and decreased incidence of severe prosthesis-patient mismatch and paravalvular leak. In patients who underwent post-TAVR CT (n = 280), prevalence of hypoattenuated leaflet thickening (HALT) at 30-day was lower in the S3UR group compared to S3/S3U (5.7% vs 16.2%; p = 0.006). In multivariate analysis, the S3UR group was independently associated with lower 1-year mortality and reduced HALT. In this propensity score-matched cohort, compared with the S3/S3U group, the S3UR group demonstrated favorable clinical outcomes and superior hemodynamic performance. In subgroup analysis, S3UR was also associated with a lower HALT incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.